Utility of different serum fibrosis markers in diagnosing patients with chronic pancreatitis and pancreatic adenocarcinoma

doi:10.4251/wjgo.v8.i8.635

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8202)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series.

Item

Count

PDF

489

WORD

345

HTML

2955

Figures (1-6)

218

Sum=4007

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

482

Download

1233

Sum=1715

Publishing Process of This Article

Item

Count

Browse

974

Download

1506

Sum=2480

Aug 15, 2016 (publication date) through Jan 12, 2025

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Clinical Trial

World J Gastrointest Oncol. Aug 15, 2016; 8(8): 635-641
Published online Aug 15, 2016. doi: 10.4251/wjgo.v8.i8.635

Open in New Tab Full Size Figure Download Figure

Figure 1 Serum hyaluronic acid in pancreatic adenocarcinoma and chronic pancreatitis patients compared to healthy controls. HA: Hyaluronic acid; PDAC: Pancreatic adenocarcinoma; CP: Chronic pancreatitis.

Open in New Tab Full Size Figure Download Figure

Figure 2 Serum transforming growth factor-β1 in pancreatic adenocarcinoma and chronic pancreatitis patients compared to healthy controls. PDAC: Pancreatic adenocarcinoma; TGF-β1: Transforming growth factor-β1; CP: Chronic pancreatitis.

Open in New Tab Full Size Figure Download Figure

Figure 3 Serum soluble fractalkine in pancreatic adenocarcinoma and chronic pancreatitis patients compared to healthy controls. s-Fr: Serum soluble fractalkine; PDAC: Pancreatic adenocarcinoma; CP: Chronic pancreatitis.

Open in New Tab Full Size Figure Download Figure

Figure 4 Serum monocyte chemoattractant protein-1 in pancreatic adenocarcinoma and chronic pancreatitis patients compared to healthy controls. MCP-1: Monocyte chemoattractant protein - 1; PDAC: Pancreatic adenocarcinoma; CP: Chronic pancreatitis.

Open in New Tab Full Size Figure Download Figure

Figure 5 Serum soluble fractalkine level depends on the duration of chronic pancreatitis. s-Fr: Serum soluble fractalkine; CP: Chronic pancreatitis.

Open in New Tab Full Size Figure Download Figure

Figure 6 In pancreatic adenocarcinoma patients with coexisting diabetes mellitus, transforming growth factor-β1 serum level was significantly higher than in pancreatic adenocarcinoma patients without endocrine insufficiency. TGF-β1: Transforming growth factor-β1.

Citation: Kozak A, Talar-Wojnarowska R, Kaczka A, Borkowska A, Czupryniak L, Małecka-Panas E, Gąsiorowska A. Utility of different serum fibrosis markers in diagnosing patients with chronic pancreatitis and pancreatic adenocarcinoma. World J Gastrointest Oncol 2016; 8(8): 635-641
URL: https://www.wjgnet.com/1948-5204/full/v8/i8/635.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i8.635